Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Radioiodine-Refractory Differentiated Thyroid Cancer
NCT01811212Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in Differentiated Thyroid Cancer (DTC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 6 months. Started May 2013; status: completed.
02
Drugs
cabozantinib
03
Conditions
Differentiated Thyroid Cancer (DTC)
Beyond the preview
Go deeper on NCT01811212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01811212.